Trial · NCT01230502
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
NCT01230502, Not applicable, Terminated, University of Wisconsin, Madison; results first posted 2014-05-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation. Trials, record NCT01230502. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01230502
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
- NCT number
- NCT01230502
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 11 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Liver Transplant
- Interventions
- Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy, data and sample collection, data and sample collection
- First posted
- 2010-10-29
- Last updated
- 2014-05-07
- Results first posted
- 2014-05-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR) | 6 months post enrollment/randomization | This outcome measure is used to determine if the reduction of calcineurin inhibitor immunosuppression leads to improved native kidney function. Native kidney function is assessed using the Modification of Diet in Renal Disease (MDRD) estimation of glomerular filtration rate (GFR) from serum or plasma creatinine samples at the reported time points. Reference intervals include: Healthy 18 years and up: 60-120 mL/min/1.73 sqm Chronic kidney disease: GFR \< 60 mL/min/1.73 sqm Kidney failure: GFR \< 15 mL/min/1.73 sqm |
| Primary | Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR) | 12 months post enrollment/randomization | This outcome measure is used to determine if the reduction of calcineurin inhibitor immunosuppression leads to improved native kidney function. Native kidney function is assessed using the Modification of Diet in Renal Disease (MDRD) estimation of glomerular filtration rate (GFR) from serum or plasma creatinine samples at the reported time points. Reference intervals include: Healthy 18 years and up: 60-120 mL/min/1.73 sqm Chronic kidney disease: GFR \< 60 mL/min/1.73 sqm Kidney failure: GFR \< 15 mL/min/1.73 sqm |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR) | 6 months post enrollment/randomization | mL/min/1.73 sqm | MEAN | |
| PRIMARY | Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR) | 12 months post enrollment/randomization | mL/min/1.73 sqm | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR) | Group 3: DSR (-), Standard of Care | 60.14 | Standard Deviation 16.39 | mL/min/1.73 sqm | |
| Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR) | Group 3: Donor Specific Regulation (DSR) -, Standard of Care | 82.4 | Standard Deviation 28.34 | mL/min/1.73 sqm |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group 3: Donor Specific Regulation (DSR) -, Standard of Care | 9 | |
| Overall Study | STARTED | Group 2 Donor Specific Regulation (DSR) +; Standard of Care | 0 | |
| Overall Study | STARTED | Group 1 Donor Specific Regulation (DSR) +, MPA Monotherapy | 0 | |
| Overall Study | COMPLETED | Group 3: Donor Specific Regulation (DSR) -, Standard of Care | 9 | |
| Overall Study | COMPLETED | Group 2 Donor Specific Regulation (DSR) +; Standard of Care | 0 | |
| Overall Study | COMPLETED | Group 1 Donor Specific Regulation (DSR) +, MPA Monotherapy | 0 | |
| Overall Study | NOT COMPLETED | Group 3: Donor Specific Regulation (DSR) -, Standard of Care | 0 | |
| Overall Study | NOT COMPLETED | Group 2 Donor Specific Regulation (DSR) +; Standard of Care | 0 | |
| Overall Study | NOT COMPLETED | Group 1 Donor Specific Regulation (DSR) +, MPA Monotherapy | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group 3: DSR (Donor Specific Regulation) (-), Standard of Care | ||
| Total, all-cause mortality | Group 2 DSR (Donor Specific Regulation) (+); Standard of Care | ||
| Total, all-cause mortality | Group 1 DSR (Donor Specific Regulation) (+),MPA Monotherapy | ||
| Total, other adverse events | Group 3: DSR (Donor Specific Regulation) (-), Standard of Care | 0 | 9 |
| Total, other adverse events | Group 2 DSR (Donor Specific Regulation) (+); Standard of Care | 0 | 0 |
| Total, other adverse events | Group 1 DSR (Donor Specific Regulation) (+),MPA Monotherapy | 0 | 0 |
| Total, serious adverse events | Group 3: DSR (Donor Specific Regulation) (-), Standard of Care | 0 | 9 |
| Total, serious adverse events | Group 2 DSR (Donor Specific Regulation) (+); Standard of Care | 0 | 0 |
| Total, serious adverse events | Group 1 DSR (Donor Specific Regulation) (+),MPA Monotherapy | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01230502
GET https://conductscience.org/api/trials/v1/NCT01230502/registered